Current Environment:

Highlights of faculty projects include:

  • Dr. David Briscoe has a long-standing interest in the understanding of chronic allograft rejection, and is studying responses that both sustain and resolve inflammation. Dr. Briscoe's team performs basic discoveries in the area of inflammation resolution, translational studies in animal models of transplantation and is developing assays for the monitoring of patients using precision biomarkers that allow for the risk stratification following transplantation. For more information please go to briscoelab.com.
  • Dr. Johannes Wedel studies the identification of novel cell types and signaling pathways that regulate T cell-dependent immune responses, with a focus on the modulation of alloimmunity and tolerance induction following transplantation.
  • Dr. Soumitro Pal is uncovering novel signaling mechanisms underlying the cause of the increased risk of cancer in transplant recipients His research focuses on how targeted therapies can prevent post-transplantation cancer, and they have given us clues into molecules that may be useful as monitors of early pre-cancer events so that preventative therapy can be initiated.
  • Dr. Markus Frank has been researching the physiological and pathological roles of the human P-glycoprotein family of ATP-binding cassette (ABC) transporters. His laboratory has cloned and characterized a novel human P-glycoprotein family member, ABCB5, which regulates maintenance and differentiation of normal tissue-specific stem cells with therapeutic capacity as a transplantable cell source for immunomodulation and tissue regeneration.